Abstract
• Background: Heparin-induced extracorporeal LDL/fibrinogen precipitation (HELP) eliminates selectively fibrinogen, LDL, cholesterol, triglycerides and LP(a) from blood plasma using extracorporeal circulation. The reduction of fibrinogen and LDL by about 50% after only one procedure immediately improves the hemorheological situation. • Method: In a prospective, randomized, controlled study over a period of 3 months, 40 patients with nonarteritic ischemic optic neuropathy (NAION) were randomly assigned to either HELP or hemodilution therapy to determine the efficacy of these two treatments on visual acuity and fields. • Results: After transformation of the Snellen acuity into logMAR units the statistical analysis did not show a significant difference between the two groups (P=0.48). An increase of the visual acuity by two or more lines was obtained in 9 patients (47.4%) of the HELP group, 10 (52.6%) remained stable and none got worse. In the hemodilution group, visual acuity increased in patients (33.4%), 9 (42.8%) remained stable and 5 (23.8%) experienced a decrease. The calculated mean sensitivity of visual fields at baseline improved statistically significantly (P<0.01) in the HELP group from 6.83 ±4.52 dB to 8.27±4.89 dB, but did not change significantly in the hemodilution group (6.25 ± 4.12 dB to 6.12±3.92 dB). • Conclusion: The HELP system seems to be safe and more effective than hemodilution in improving the hemorheological and the functional situation in NAION and could be a promising regimen in the treatment, of NAION.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Acheson JF, Sanders MD (1994) Coagulation abnormalities in ischaemic optic neuropathy. Eye 8: 89–92
Arnold AC, Hepler RS (1994) Natural history of nonarteritic anterior ischemic optic neuropathy. J Neurophthalmol 14: 66–69
Chisholm IA (1969) Optic neuropathy of recurrent blood loss. Br J Ophthalmol 53: 289–295
Daniel WW (1991) Biostatistics: a foundation for analysis in health sciences, 5th edn. Wiley, New York, pp 586–592
Dintenfass L, Kammer S (1977) Plasma viscosity in 615 subjects. Effects of fibrinogen, globulin and cholesterol in normals, peripheral vascular disease, retinopathy, and melanoma. Biorheology 14:247–251
Foulds WS (1969) Visual disturbance in systemic disorders, optic neuropathy and systemic disease. Trans Ophthalmol Soc UK 89: 125–146
Haas A, Walzl M, Faulborn J, Walzl B, Berglöff J, Eckhardt M (1994) Heparin-induzierte extracorporale LDL-Präzipitation (H.E.L.P.) — eine neue Therapiemöglichkeit bei Gef\verschlüssen der Netzhaut. Erste Ergebnisse. Ophthalmologe 91: 283–287
Haas A, Walzl M, Eckhardt M, Walzl B, Faulborn J, Feigl B (1996) Influence of a single H.E.L.P. application on hemorheology and retinal hemodynamics. Ophthalmologica 210: 171–174
Hansen LL, Wick J, Danisevskis M, Schrader W (1991) Isovolömische Hémodilution bei nicht arteriitischer anteriorer Optikusneuropathie. Fortschr Ophthalmol 88: 487–489
Hayreh SS (1972) Occlusion of the posterior ciliary artery. III. Effects on the optic nerve head. Br J Ophthalmol 56: 754–764
Hayreh SS (1974) Anterior ischemic optic neuropathy. 1. Terminology and pathogenesis. Br J Ophthalmol 58:955–966
Hayreh SS (1974) Anterior ischaemic optic neuropathy. III. Treatment, prophylaxis, and differential diagnosis. Br J Ophthalmol 58: 981–989
Hoffkes HG, Saeger-Lorenz K, Ehrly AM (1991) Optimal hematocrit in patients with intermittent claudication. Exercise-induced muscle tissue oxygen pressure after stepwise hemodilution. AMA 18 [Suppl 1]: 16–19
Kannel WB, D'Agostino RB, Wilson PWF, Belanget AJ, Gagno DR (1990) Diabetes, fibrinogen and risk of cardiovascular disease: the framingham experience. Am Heart J 120: 672–676
Kleophas W, Leschke M, Tschöpe D (1990) Akute Wirkung der extrakorporalen LDL-Cholesterin- und Fibrinogen-Elimination auf Blutrheologie und Mikrozirkulation. Dtsch Med Wochenschr 115: 3–7
Lechner H, Walzl M, Walzl B, Kleinert G, Köck T (1991) The influence of H.E.L.P. System in cerebrovascular disease, weighted on hemorheological factors. Med Biophysics 2: 147–150
Lechner H, Walzl M, Walzl B, Freidl W (1992) H.E.L.P. — a possibility to change the hemorheologic profile in cerebrovascular disease. Clin Hemorheol 12:705–711
Martin M, Hirdes E, Auel H (1976) Defibrinogenation in patients suffering from severe intermittent claudication: a controlled study. Thromb Res 9: 47–57
Meade TW, Vickers MW, Thompson SG, Seghatchian MJ (1985) The effect of physiological levels of fibrinogen on platelet aggregation. Thromb Res 38: 527–532
Movsas T, Kelman SE, Elman MJ, Miller NR, Dickersin K, Min YL (1991) The natural course of non-arteritic ischemic optic neuropathy. Invest Ophthalmol Vis Sci Suppl 42: 951–958
Ramoling MW, Whittingstall P, Linderkamp O (1984) The effects of fibrinogen and its plasmin degradation products on the theology of erythrocyte suspension. Clin Hemorheol 4: 533–543
Repka MX, Savino PJ, Schatz NJ, Sergott RC (1983) Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol 96: 478–483
Sadoshima S, Tanaka K (1979) Fibrinogen and low density lipoprotein in the development of cerebral artherosclerosis. Arteriosclerosis 34: 93–103
Schuff-Werner P, Schütze E, Seyde W, Eisenhauer T, Janning G, Armstrong VW, Seidel D (1989) Improved hemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparininduced extracorporeal LDL precipitation (H.E.L.P.). Eur J Clin Invest 19: 30–37
Schuff-Werner P, Schütze E, Eisenhauer T, Armstrong VW (1992) Longterm fibrinogen lowering therapy by regular LDL/fibrinogen precipitation with the HELP system. In: Ernst E, Koenig W, Lowe GDO, Meade TW (eds) Fibrinogen: a “new” cardiovascular risk factor. Blackwell-MZV, Vienna, pp 403–407
Seidel D (1990) the H.E.L.P. system: an efficient and safe method of plasmatherapy in the treatment of severe hyperchole sterolemia. Ther Umschau 47: 514–519
Seplowitz AH, Chien S, Smith FR (1981) Effects of lipoproteins on plasma viscosity. Arterosclerosis 38: 89–95
Sergott RC, Cohen MS, Bosley TM, Savino PJ (1989) Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy. Arch Ophthalmol 107: 1743–1754
Talks SJ, Chong NH, Gibson JM, Dodson PM (1995) Fibrinogen, cholesterol and smoking as risk factors for non-arteritic anterior ischaemic optic neuropathy. Eye 9: 85–88
The Ischemic Optic Neuropathy Decompression Trial Research Group (1995) Optic nerve decompression surgery for anterior ischemic optic neuropathy. JAMA 273: 625–632
Walzl M, Lechner P, Walzl B (1992) Application of HELP in PVOD -preliminary results. In: Ernst E, Koenig W, Lowe GDO, Meade TW (eds) Fibrinogen: a “new” cardiovascular risk factor. Blackwell-MZV, Vienna, pp 419–422
Walzl M, Walzl B, Niederkorn K, Horner S, Lechner H (1993) Reopening of internal carotid artery occlusion during heparin-induced LDL precipitation (HELP) associated with improved hemorheology. Wien Klin Wochenschr 105: 350–354
Wilhelmsen L, Svärdsudd K, Korsan-Bengsten K, Larrson B, Welin L, Tibblin G (1984) Fibrinogen as a risk factor for stroke and myocardial infection. N Engl J Med 311: 501–505
Wolf S, Schulte-Strake U, Bertram B, Schulte K, Arend O, Reim M (1993) Hämodilutionstherapie bei Patienten mit akuter vorderer ischémischer Optikusneuropathie. Fortschr Ophthalmol 90: 21–26
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haas, A., Walzl, M., Jesenik, F. et al. Application of HELP in nonarteritic anterior ischemic optic neuropathy: A prospective, randomized, controlled study. Graefe's Arch Clin Exp Ophthalmol 235, 14–19 (1997). https://doi.org/10.1007/BF01007832
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01007832